17th North American Regional ISSX Meeting (October 16

P231

Automated Metabolite Cross-Correlation as a Tool for Faster Decision Making
Hesham Ghobarah, AB SCIEX; Russell J. Mortishire-Smith, Johnson & Johnson Pharmaceutical Research and Development; Pascale Proost, Johnson & Johnson Pharmaceutical Research and Development; Alina Dindyal-Popescu, AB SCIEX; Hai Ying, AB SCIEX

P232

Deuterium-Substituted Lapatinib Isotopologs Exhibit Reduction in O-debenzylation and Metabolic Shunting
Vinita Uttamsingh, CoNCERT Pharmaceuticals, Inc.; Craig Masse, CoNCERT Pharmaceuticals, Inc.; Sophia Nguyen, CoNCERT Pharmaceuticals, Inc.; Adam Morgan, CoNCERT Pharmaceuticals, Inc.; Changfu Cheng, CoNCERT Pharmaceuticals, Inc.; Bhaumik Pandya, CoNCERT Pharmaceuticals, Inc.; Richard Gallegos, CoNCERT Pharmaceuticals, Inc.; Gary Bridson, CoNCERT Pharmaceuticals, Inc.; Lijun Wu, CoNCERT Pharmaceuticals, Inc.; Roger Tung, CoNCERT Pharmaceuticals, Inc.; Scott Harbeson, CoNCERT Pharmaceuticals, Inc.

P233

High-Resolution Accurate Mass-Measurements and Metabolite Identification: an Automated Approach Using Fragment Prediction in Combination with Fragment Ion Search (FISh)
Janine Wank, Swiss Bioanalytics; Winfried Wagner-Redeker, Swiss Bioanalytics; Anthony Taylor, Thermo Fisher Scientific; Rose L. Herbold, Thermo Fisher Scientific; Paul-Gerhard Lassahn, Swiss Bioanalytics

P234

Identification and Determination of the Percent AUC of Five Metabolites of a Tetrahydropyran-containing Drug, Co-eluting as a Broad Peak due to the Presence of Metabolites Undergoing Conformational Change during HPLC Radiochromatography
Heasook Kim-Kang, XenoBiotic Laboratories, Inc.; Zheming Gu, XenoBiotic Laboratories, Inc.; LiQuan Wang, XenoBiotic Laboratories, Inc.; Shelby R. Anderson, Eli Lilly and Company; Elizabeth Joshi, Eli Lilly and Company

P235

Identification and Semi-quantification of Circulating Metabolites of BIIB021 in First-in-Human (FIH) Studies
Lin Xu, BiogenIdec; Caroline Woodward, BiogenIdec; Min Chang, BiogenIdec; Samina Khan, BiogenIdec; Chandra Prakash, BiogenIdec

P236

In Vivo Disposition and Pharmacokinetics and In Vitro Inhibition and Induction Profiles of Saxagliptin, a Potent Inhibitor of Dipeptidyl Peptidase 4, in Human
Hong Su, Bristol-Myers Squibb; Lisa J. Christopher, Bristol-Myers Squibb; Ramaswamy A. Iyer, Bristol-Myers Squibb; Kai Cao, Bristol-Myers Squibb; Samuel Bonacorsi, Bristol-Myers Squibb; David Boulton, Bristol-Myers Squibb; William G. Humphreys, Bristol-Myers Squibb

P237

In vitro Metabolism of BIIB021, an Oral Heat Shock Protein Hsp90 Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans
Lin Xu, BiogenIdec; Caroline Woodward, BiogenIdec; Chandra Prakash, BiogenIdec

P238

In-vitro and in-vivo identification of new domperidone metabolites by LC-ESI-MS/MS
Amir S. B. Youssef, Temple University School of Pharmacy; Murali Pathikonda, Temple University School of Medicine; Upendra Argikar, Novartis Institutes for Biomedical Research Inc.; Henry P. Parkman, Temple University School of Medicine; Swati V. Nagar, Temple University School of Pharmacy

P239

Pharmacokinetics, Disposition and Metabolism of AZD5455, a Selective Enkephalinergic Agonist, in Rats and Dogs
Yan Li, AstraZeneca; Down Perry, AstraZeneca; Scott Grimm, AstraZeneca

P240

Unexpected Mass Changes as a Result of Hydrogen/Deuterium Exchange
Austin Li, Cephalon, Inc.; Steven Ring, Cephalon, Inc.; Erya Yu, Cephalon, Inc.; James P. Chovan, Cephalon, Inc.

P241

gADME: Characterization of CYP2D6 activity of mutant proteins using control substrates and CNS-active drugs
Robert R. Annand, Apredica; Mohammed Taimi, Apredica; Takayuki Nakano, Apredica; Helen Gill, Cyprotex; Clive Dilworth, Cyprotex Discovery; Katya Tsaioun, Apredica

Metabolic Profiling